I predict that the announcements, when they come will include:
1 publication of the top-line percentage-agreement figures for all included disease conditions
2 analysis of the impact on the likelihood of FDA approval
3 tentative programme and time-line for commercialisation
It will be a highly professional job, as this team has always produced, providing accurate and full disclosure, a comprehensive investor presentation, and a concrete and verifiable business plan going forward. It will involve very much more than just faxing a copy of the study group's numbers to the ASX, as some posters seem to expect. If the management did that then they could rightly be criticised for not doing their job. Resapp is a
business. We expect our management team to
manage the business too! They always have. That is what they will be doing now.
Finally, I've been reading a lot of comments like, "we'll know on the 9th". You may not know on the 9th! As
@gcdany pointed out the 9th is an
estimate. The suspension will end when the announcement is made if it is made on or before 9th August. But the 9th may come and go and if the company is not ready to release the announcement(s) it will apply for an extension. I suggest
everybody reads the second paragraph of the request for suspension:
The Company requests that the voluntary suspension end on the date the anticipated announcement referred to above is released to the market which the Company anticipates will occur by 9 August 2017.
Also, to save anybody the trouble, here is a dictionary definition of the word "anticipates":
to expect; look forward to; be sure of:
to anticipate a favorable decision.
http://www.dictionary.com/browse/anticipate (meaning 2)
While you're reading, this might help you understand the nature of voluntary suspensions:
http://www.asx.com.au/documents/about/guidance-note-16-compare.pdf (page 8)
